Intelligence · Clinical Pipeline
AstraZeneca Pipeline
All ClinicalTrials.gov programs at AstraZeneca — phase, modality, and trial IDs.
- Programs
- 249
Quick answer
AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.
AstraZeneca AB
Crohn's disease
1 trial -
Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer
AstraZeneca AB
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
1 trial -
Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment
AstraZeneca AB
Moderate Renal Impairment, Heart Failure
1 trial -
TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets
AstraZeneca AB
Metastatic Breast Cancer
1 trial -
Calquence 100 mg film-coated tablets, Calquence 100 mg film-coated tablets
AstraZeneca AB
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
1 trial -
DS-8201a
AstraZeneca AB
Treatment of patients with HER2-positive breast cancer with or without brain metastasis
1 trial -
Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe
AstraZeneca AB
Severe eosinophilic asthma
1 trial -
The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension
AstraZeneca AB
Chronic Obstructive Pulmonary Disease
1 trial
Frequently asked questions
How many pipeline programs does AstraZeneca have?
249 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs